24.58
Schlusskurs vom Vortag:
$24.42
Offen:
$24.6
24-Stunden-Volumen:
819.16K
Relative Volume:
0.65
Marktkapitalisierung:
$15.77B
Einnahmen:
$2.62B
Nettoeinkommen (Verlust:
$966.70M
KGV:
16.39
EPS:
1.5004
Netto-Cashflow:
$1.09B
1W Leistung:
+5.49%
1M Leistung:
+12.80%
6M Leistung:
+10.07%
1J Leistung:
-8.99%
Genmab Adr Stock (GMAB) Company Profile
Vergleichen Sie GMAB mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
GMAB
Genmab Adr
|
24.58 | 14.40B | 2.62B | 966.70M | 1.09B | 1.5004 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
396.71 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
592.25 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
457.04 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
662.77 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
312.73 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-01 | Herabstufung | Bernstein | Mkt Perform → Underperform |
2025-03-11 | Hochstufung | William Blair | Mkt Perform → Outperform |
2025-02-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
2024-09-04 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2024-08-20 | Herabstufung | JP Morgan | Overweight → Neutral |
2024-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2024-02-23 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2024-01-22 | Herabstufung | Citigroup | Neutral → Sell |
2023-12-06 | Hochstufung | UBS | Neutral → Buy |
2023-11-10 | Hochstufung | Deutsche Bank | Hold → Buy |
2023-11-08 | Hochstufung | DNB Markets | Sell → Buy |
2023-10-18 | Eingeleitet | Exane BNP Paribas | Underperform |
2023-09-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2023-08-24 | Eingeleitet | BTIG Research | Buy |
2023-07-14 | Eingeleitet | HSBC Securities | Buy |
2023-05-31 | Eingeleitet | UBS | Neutral |
2023-05-12 | Eingeleitet | Morgan Stanley | Underweight |
2022-12-20 | Herabstufung | Citigroup | Buy → Neutral |
2022-11-14 | Eingeleitet | William Blair | Mkt Perform |
2022-11-11 | Herabstufung | Deutsche Bank | Buy → Hold |
2022-06-24 | Eingeleitet | BMO Capital Markets | Market Perform |
2022-05-02 | Eingeleitet | Cowen | Market Perform |
2022-03-16 | Hochstufung | UBS | Neutral → Buy |
2022-01-31 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2022-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
2021-12-01 | Eingeleitet | Berenberg | Sell |
2021-09-16 | Herabstufung | Jefferies | Buy → Hold |
2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2021-08-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2021-04-20 | Eingeleitet | Deutsche Bank | Buy |
2021-01-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-09-23 | Herabstufung | Bryan Garnier | Neutral → Sell |
2020-09-08 | Eingeleitet | SVB Leerink | Mkt Perform |
2020-06-25 | Herabstufung | Credit Suisse | Outperform → Neutral |
2020-04-23 | Eingeleitet | Credit Suisse | Outperform |
2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
2020-01-13 | Eingeleitet | SunTrust | Buy |
2019-12-12 | Herabstufung | Deutsche Bank | Buy → Hold |
2019-09-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
2019-09-12 | Hochstufung | JP Morgan | Neutral → Overweight |
2019-08-12 | Eingeleitet | Guggenheim | Buy |
2019-08-12 | Eingeleitet | Morgan Stanley | Overweight |
2019-08-12 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Genmab Adr Aktie (GMAB) Neueste Nachrichten
IBD Rating Upgrades: WR Berkley Flashes Improved Technical Strength - inkl
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors - GlobeNewswire Inc.
What is HC Wainwright’s Forecast for Genmab A/S Q1 Earnings? - Defense World
BioNTech ADR Meets 80-Plus Relative Strength Rating Benchmark - inkl
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by LPL Financial LLC - Defense World
What is William Blair’s Forecast for Genmab A/S Q3 Earnings? - Defense World
Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade - MSN
Genmab and BioNTech’s Innovative Cancer Trial: A Market Game Changer? - The Globe and Mail
BioNTech and Genmab’s Promising Colorectal Cancer Study: A Potential Game-Changer? - TipRanks
GMAB: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com
Genmab and BioNTech’s Promising Cancer Study: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Genmab and BioNTech’s Innovative Cancer Trial: A Potential Game-Changer? - The Globe and Mail
Genmab and BioNTech SE’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Stake Lessened by Cerity Partners LLC - Defense World
Genmab and BioNTech Launch Promising Study for Advanced Colorectal Cancer Treatment - The Globe and Mail
Genmab (GMAB) Upgraded to Strong Buy: Here's Why - MSN
Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High? - Zacks Investment Research
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by Envestnet Asset Management Inc. - Defense World
Genmab Bets On Antibody Innovations As Royalties Rule The Day - Finimize
Genmab A/S FY2025 EPS Estimate Increased by William Blair - Defense World
Genmab AS (ADR) (US3723032062.SG) latest stock news and headlines - yahoo.co
Genmab A/S (NASDAQ:GMAB) Price Target Raised to $46.00 - Defense World
Genmab and BioNTech’s Promising Cancer Trial: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1042 Study: A New Hope for Cancer Treatment? - TipRanks
Genmab and BioNTech’s Immunoradiotherapy Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Genmab and BioNTech’s Pioneering Cancer Trial: A Potential Game-Changer? - The Globe and Mail
Genmab and BioNTech’s Promising Immunoradiotherapy Study for Metastatic Tumors - TipRanks
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Genmab and BioNTech’s GEN1056 Study: A Potential Game-Changer in Oncology - TipRanks
Mirae Asset Global Investments Co. Ltd. Cuts Stock Position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) - Defense World
Envestnet Portfolio Solutions Inc. Sells 6,066 Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) - Defense World
GAMMA Investing LLC Boosts Holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB) - Defense World
Why Genmab Stock Smashed It On Monday - Barchart.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Applied Dna Sciences Inc (APDN)’s Day in Review: Closing at 0.85, Down by -2.41 - DWinneX
Stock Surge: Genmab ADR (GMAB) Closes at 19.42, Marking a -5.73 Increase/Decrease - DWinneX
Market Momentum Report: Evercore Inc (EVR)’s Positive Close at 216.74 - DWinneX
Investing in Take-Two Interactive Software, Inc (TTWO) Is Getting More Attractive - knoxdaily.com
Investing in Genmab ADR (GMAB): What You Must Know - knoxdaily.com
Nucor Corp (NUE) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
EWTX Stock Sees Surge of Approximately 4.24% in Last Five Days - knoxdaily.com
GMAB or RGEN: Which Is the Better Value Stock Right Now? - Yahoo Finance
Should Value Investors Buy Genmab (GMAB) Stock? - Yahoo Finance
Finanzdaten der Genmab Adr-Aktie (GMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):